Abstract
Background Lifestyle modification has been shown to improve blood pressure (BP) control, but its practice is poor among patients with hypertension. Thus, measures that would help patients with hypertension achieve positive lifestyle modification would improve BP control. The study aimed to determine the effect of motivational interviewing on lifestyle modification and blood pressure control among patients with hypertension attending the Family Medicine Clinics of Irrua Specialist Teaching Hospital (ISTH), Irrua, Nigeria.
Methods The study was a randomised control trial (PACTR202301917477205) of 250 hypertensive adults between 18 and 65 years presenting to the Family Medicine Clinics of ISTH randomised into intervention and control groups. Those in the intervention group were given monthly motivational interviewing (MI) on lifestyle modification in addition to standard care for the management of hypertension while those in the control group got standard care only for 6 months. Both groups were assessed at baseline and 6 months. Data was analysed with Stata version 17 (StataCorp LLC) with level of significance at 0.05. Primary outcome was lifestyle modification while secondary outcome was BP control both at 6 months.
Results The age of the participants ranged from 24 to 65 years with a mean age of 51.5 ± 10.0 years. The blood pressure control at baseline was 24%. At the end of the six-month study, there was a statistically significant improvement in the lifestyle pattern of the intervention group compared to control except smoking in which the difference was not statistically significant (p=0.150). Blood pressure control significantly improved from 24% at baseline to 48% post-intervention (p=0.014).
Conclusion The study found a significant positive association between motivational interviewing and lifestyle modification. The study also found a significant improvement in blood pressure control following motivational interviewing. There is a need to incorporate motivational interviewing into the management of hypertension for better outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
PACTR202301917477205
Funding Statement
The research was funded by the Tertiary Institution Trust fund through the Tetfund Staff Development and Training Scheme with the sum of four million five hundred thousand naira (N4,500,000).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was sought and obtained for the study from the Ethics and Research Committee of Irrua Specialist Teaching Hospital, where the research was conducted (ISTH/HREC/20230802/446). Written consents were obtained from respondents before the study after a detailed explanation to them.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data used are available in the manuscript and also deposited in th Pan African Clinical Trial Registry (PACTR202301917477205)
